CRISPR Q3 net loss narrows; exa-cel PDUFA: Dec 8 (SCD) & Mar 30, 2024 (TDT)

CRISPR Therapeutics AG

2023-Q3 EPS reported -$3.07 revenue$170,000,000

PDUFA target action date for exa-cel in sickle cell disease: Dec 8, 2023; for beta thalassemia: March 30, 2024.
Net loss narrowed to $112.2M in Q3 2023 from $174.5M in Q3 2022; cash $1.74B.
R&D expenses decreased to $90.7M from $116.6M; G&A down to $18.3M from $27.0M.
Initiated Phase 1 trial for CTX310 targeting ANGPTL3; CTX320 on track for clinic in H1 2024.
Proposed election of Sandy Mahatme to Board at 2024 annual meeting.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CRISPR Therapeutics AG reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-23-059461

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.